quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:25:11·43d
INSIDERFiling
Anika Therapeutics Inc. logo

SEC Form 4 filed by Anika Therapeutics Inc.

ANIK· Anika Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • ANIK
    Anika Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 17UpdateB. Riley Securities$21.00
  • Nov 1UpdateBarrington Research$25.00
  • Aug 14UpdateBarrington Research$24.00
  • Mar 7UpdateBarrington Research-
  • Nov 9UpdateBarrington Research$31.00
  • Oct 14UpdateStephens$26.00

Related

  • PR7d
    Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
  • PR8d
    Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
  • PR15d
    Telix Strengthens Board with Additional Director Appointments
  • PR20d
    Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Anika Therapeutics Inc.
  • INSIDER31d
    SEC Form 4 filed by Mcleod Ian
  • INSIDER37d
    EVP, General Counsel, Corp Sec Colleran David converted options into 15,837 shares, was granted 4,694 shares and covered exercise/tax liability with 6,061 shares, increasing direct ownership by 27% to 67,570 units (SEC Form 4)
  • INSIDER37d
    President and CEO Griffin Stephen D. was granted 6,412 shares, covered exercise/tax liability with 5,944 shares and converted options into 12,824 shares, increasing direct ownership by 125% to 23,963 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022